Currently prescribed medications for the treatment of Alzheimer’s disease (AD) that are based on acetylcholinesterase inhibition only offer symptomatic relief but do not provide protection against neurodegeneration. Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.